Skip To Main Content
João Salgueiro Mouta on Muck Rack

João Salgueiro Mouta

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with João Salgueiro

Contact João Salgueiro, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial

|
By Sibylle Loibl, Gong Tang, Valentina Nekljudova, Priya Rastogi, Sivaramakrishna P. Rachakonda, Mattea Reinisch, Joshua Acosta, Andreas Schneeweiss, Christie J. Hilton, Sabine Seiler, Rohit Bhargava, Thomas Karn, Patricia Cortazar, Fernando Moreno, Jay Andersen, Stephani Christensen, Peter Klare, Sujatha Murali, Serafín Morales, Jens Huober, Jean-François Boileau, Dominique K. Boudreau, Julia Teply-Szymanski, João Salgueiro Mouta, Eleftherios P Mamounas, Carsten Denkert, Norman Wolmark, Charles E. Jr., Álvaro Rodríguez-Lescure, Peter J. Polewski
| Nature Verified
Abstract Triple-negative breast cancer (TNBC) is an aggressive subtype with an activated tumor immune microenvironment. The multicenter, multinational, double-blinded NSABP B-59/GeparDouze trial evaluated the addition of atezolizumab (atezo) (773 patients randomized) or placebo (777 patients) to sequential taxane–carboplatin–anthracycline-based neoadjuvant chemotherapy in stage II–III TNBC.
Open in Who Shared Issue with article?

Grendel, Beowulf and fate of mankind hangs in the balance

|
By Alexander Jarvis, Shelly Sanchez Te., João Salgueiro Mouta, Arletha M.
| slideshare.net
Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our User Agreement and Privacy Policy. Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our Privacy Policy and User Agreement for details.
Open in Who Shared Issue with article?
See all 2 articles